Home » Topics » Substance use and poisoning, BioWorld Science

Substance use and poisoning, BioWorld Science
RSS

Embera NeuroTherapeutics obtains NIDA grant for EMB-001 development

Oct. 5, 2010

Cleveland BioLabs reports on second safety study of CBLB-502

Oct. 1, 2010

FDA approves phase Ib ibudilast trial in methamphetamine-dependent subjects

Sep. 29, 2010

FDA committee recommends approval of Vivitrol for opioid dependence

Sep. 20, 2010

Nabi enters agreement with Diosynth for manufacture of NicVAX nicotine vaccine

Sep. 7, 2010

Cellerant awarded BARDA contract to develop ARS treatment

Sep. 2, 2010

ImmuneRegen to submit proposal for funding Homspera development

Sep. 1, 2010

FDA approves Suboxone sublingual film

Sep. 1, 2010

BTG to receive marketing rights for Nycomed's CroFab and DigiFab

Sep. 1, 2010

Escitalopram prevents relapse in patients with alcoholism and comorbid affective disorders

Aug. 31, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...
$Silhouette of head and brainwith fractal art$
ATAI-dyed Lilly tees up in psychedelics, finds $3.8B fit
BioWorld
Rumblings that psychedelic treatments would soon be ready for prime time gained credence aplenty, and shares of Ataibeckley Inc. (NASDAQ:ATAI) ended July 16 at...